“If I didn’t believe the ActJect would serve Soldiers, Marines, Airmen, Sailors, Guardsmen and our civilian first-responders better than what we already have “on the shelf,” I wouldn’t be involved in its development. I am proud to contribute to the development of this revolutionary device.”
Kevin C. O’Connor, D.O., FAAFP, COL (Ret), MC, MFS, USA
Physician to the 47th Vice President of the United States
White House Physician, 2006-2009
Former Command Surgeon, Army Special Missions Unit
- Low Cost
- Easy to Use
- Non-Slip Sanoprene Grip
- Shielded Needle
- Military Grade
• Low Cost
• Easy to Use
• Non-Slip Sanoprene Grip
• Shielded Needle
• Military Grade
Tactical military needs are unique, and current auto-injectors have been failing our soldiers for decades.
Action Medical is reinventing auto-injectors with a mission to save the lives of U.S. soldiers.
As prices skyrocket, consumers and EMTs resort to syringes. Many doctors and patient advocates warn that it’s more complicated and can take longer to get the correct dose and administer it safely with a syringe.
No Single Solution Exists
Today, no competing device exists that can be quickly or easily converted to intramuscular, intranasal, intravenous or intraosseous use. In military and emergency medicine situations, seconds can mean life or death.
Unreliable & Dangerous
Recalls, market withdrawals, injuries and failures. Auto-injectors are simply not reliable enough, are too complicated and are allowing too many deaths.
Too Many Parts
More parts means more complications and the greater potential for failure–not to mention added manufacturing costs which gets passed on to the customer.
Extreme situations are unique. Hands can be slippery with blood, the environment can be wet and visibility low. In certain circumstances an auto-injector needs to puncture a MOPP-4 suit. Competing auto-injectors are not designed to meet these needs.
Every day in the U.S. there are more than 2,100 needlestick injuries affecting our medical community and soldiers. The Needlestick Safety & Prevention Act outlines the need for “safer medical devices” with engineered sharps injury protections.
Simple Design, Fewest Parts
We’ve created an ultra-reliable auto-injector that’s easier to use. Minimalism is also how we achieved reliability and lower manufacturing cost. Only 5 parts plus the needle assembly.
Ideal For All Ages
ActJect is ideal for children since the appearance of the shielded needle is less scary than a syringe, and the shielding extends back over the needle after injection and auto-locks to prevent needlestick.
Crush-Resistant & Reliable
Tactical military needs are unmet in the relentless pursuit of saving the lives of US soldiers in the battlefield. No true solution has existed until now to meet these unique needs.
Rugged & Waterproof
ActJect employs a shielded needle to prevent needle-stick, and has a waterproof casing to work in the most rugged conditions. It’s designed to puncture a MOPP-4 suite if needed in the harshest of environments.
Smaller & Easier to Carry
A reliable device that’s easier for first-responders, emergency rooms, health departments, and soldiers to carry can be the difference between life and death where seconds matter.
ActJect Does it All
Our innovative design allows it to be quickly and easily converted to intramuscular, intranasal, intravenous or intraosseous use. This is critical in military and emergency medicine situations.
Frank X. Osborne
Frank Osborne founded HawkGrips, a multi-million dollar medical device and education company that he grew to become the premier brand in the rehabilitation industry. In 2016, he was recognized by the White House Medical Unit for “Outstanding Achievement in Support of the President of the United States.” Prior to this he founded and self-funded two successful real estate companies.
Thor Halseth is principal and founder of many successful companies including Halseth Design, LLC. He’s the inventor or co-inventor of record for 62 patents of which 52 are safety needle patents, and Thor currently has 33 patents pending. He helped take Med-Design Corporation public and also co-founded NOW Medical LLC, which was subsequently sold to C.R. Bard. All of his safety needle patents are now owned by Becton Dickinson.
Dr. Kevin O'Connor
Chief Medical Officer
After 22 years in the U.S. Army and a decade at the White House, Col. O’Connor is now the Director of Executive Medicine at The GW Medical Faculty Associates in Washington, DC. He also serves as Medical Director of International & Diplomatic Affairs at George Washington University Hospital, and Associate Professor of Medicine and Senior Medical Advisor for health sciences programs at George Washington University School of Medicine & Health Sciences in the nation’s capital.
Chief Operating Officer
Was the CEO of Vernitron Medical Products, the manufacturer of the Ped-O-Jet injection device that inoculated almost 500 million people around the world beginning with US soldiers and military recruit immunizations from 1965 to 1998; the Worldwide WHO/CDC Smallpox Eradication Campaign; the 1976 US CDC Swine Flu Program; the 1988 Brazilian Meningococcal Meningitis Program, and the 1992 WHO Brazilian Measles Eradication Program. With more than 40 years business experience, a graduate of the University of Maryland.
VP of Finance
Barbara has been a certified public accountant (CPA) since 1991. She ensures adequate procedures are in place to safeguard the company’s assets and optimize cash flow. Barbara serves on the Board of Directors of the Central Bucks Chapter of the National Charity League. Barbara holds a bachelor of science degree in business administration from Widener University, and earned her master in business administration (MBA) degree from Pepperdine University.
VP of Manufacturing
46 years manufacturing experience. Creates tooling from sketches, blueprints, specifications & models for the fabrication of dies, tools and assemblies, ensuring safety & maximum efficiency. In a typical year, he makes 10-25 major ‘tools’: ultra-precision plastic injection molds & stamping die to high precision tolerances. Mark’s tooling has created an estimated 50 billion final parts. Mark’s experience ranges from ‘startup-ideas-turned-into-final-products’ to troubleshooting massive ultra-fast production lines for higher quality.
Dr. Peter G. Goldschmidt, MD, DrPH, DMS
Dr. Goldschmidt has more than 40 years of experience in healthcare quality management and is president of the World Development Group, a healthcare business-development company. He has served as a principal investigator for many research projects and spent almost a decade serving the Agency for Healthcare Research and Quality as principal consultant for implementation of the Patient Safety and Quality Improvement Act of 2005, including the design of common formats for reporting and analyzing patient-safety events.
Lori A. Hoffman
Ms. Hoffman is the Senior Director of Alliance Management for Frontida BioPharm, Inc., a contract development and manufacturing organization (CDMO). She has more than 27 years of broad pharmaceutical industry experience in active pharmaceutical ingredient (API) and finished-dosage research and development, project management, pipeline management, and business development. Previously, she spent nine years at Sagent Pharmaceuticals, as the director of project management for sterile injectable projects.
Thani Jambulingam, PhD
Dr. Jambulingam is a professor in the Department of Pharmaceutical and Healthcare Marketing at the Erivan K. Haub School of Business, Saint Joseph’s University (SJU), in Philadelphia. He teaches in the Pharmaceutical & Healthcare Marketing MBA for Executives program and the undergraduate program in Pharmaceutical and Healthcare Marketing. Trained at Harvard University, Dr. Jambulingam and worked in marketing at GlaxoSmithKline before earning his PhD at the University of Wisconsin in Madison.
Timothy S. Callahan
Mr. Callahan is an accomplished global-life-sciences operating executive and board member with 25 years of experience in the biopharma industry, most recently with the Actavis plc (now Allergan) organization. He has provided independent advisory and board services to pharmaceutical, biotech, and life-science companies going through a transformation in their business; particularly development-stage companies making the transition to commercial, and commercial-stage companies seeking to rapidly accelerate growth.
Mr. Weddle is a business and technology consultant. He has built and sold successful high-tech start-ups, including one sold to Rockwell Automation for $200M. He has helped create another half dozen startups, and as a consultant for Ernst & Young helped senior most leadership for Disney, Intel, Ericsson, Amgen, Ford, Boeing, Sprint, Southwest Airlines, Hilton, Mattel, Warner Brothers, and others. He also has extensive experience with U.S. Government having held TS and TS/SCI positions.
Richard P. Jaffe
Practices in the area of private equity law with a focus on control and non-control investments, fund formation and operation, divestitures, corporate finance and venture capital financing, particularly in the technology and manufacturing industries. Regularly represents private equity funds, investors and strategics in corporate transactions and advises business owners on raising capital to grow and exit their companies, and structuring public and private securities offerings, mergers, acquisitions.